Do analysts rate PTIX or AQB?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Atrinsic 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 AquaBounty Technologies 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher valuation & earnings, PTIX or AQB?

AquaBounty Technologies is trading at a lower price-to-earnings ratio than Atrinsic, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Atrinsic N/A N/A -$5.53M $2.23 0.48 AquaBounty Technologies N/A N/A -$18.49M -$0.82 N/A

Is PTIX or AQB more profitable?

Atrinsic's return on equity of 0.00% beat AquaBounty Technologies' return on equity. Company Net Margins Return on Equity Return on Assets Atrinsic N/A N/A -379.72% AquaBounty Technologies N/A -147.07% -28.73%

Do analysts prefer PTIX or OSRH?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Atrinsic 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 OSR 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher valuation & earnings, PTIX or OSRH?

Atrinsic has higher earnings, but lower revenue than OSR. OSR is trading at a lower price-to-earnings ratio than Atrinsic, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Atrinsic N/A N/A -$5.53M $2.23 0.48 OSR $1.81M 4.37 -$27.06M -$0.37 N/A

Is PTIX or OSRH more profitable?

Atrinsic has a net margin of 0.00% compared to OSR's net margin of -593.15%. Atrinsic's return on equity of 0.00% beat OSR's return on equity. Company Net Margins Return on Equity Return on Assets Atrinsic N/A N/A -379.72% OSR -593.15% -8.36% -6.24%

Do analysts recommend LABT or PTIX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lakewood-Amedex Biotherapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Atrinsic 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better valuation & earnings, LABT or PTIX?

Lakewood-Amedex Biotherapeutics is trading at a lower price-to-earnings ratio than Atrinsic, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Lakewood-Amedex Biotherapeutics N/A N/A -$3.85M -$4.75 N/A Atrinsic N/A N/A -$5.53M $2.23 0.48

Is LABT or PTIX more profitable?

Company Net Margins Return on Equity Return on Assets Lakewood-Amedex Biotherapeutics N/A N/A N/A Atrinsic N/A N/A -379.72%

Does the media favor LABT or PTIX?

In the previous week, Lakewood-Amedex Biotherapeutics had 3 more articles in the media than Atrinsic. MarketBeat recorded 4 mentions for Lakewood-Amedex Biotherapeutics and 1 mentions for Atrinsic. Lakewood-Amedex Biotherapeutics' average media sentiment score of 0.78 beat Atrinsic's score of 0.00 indicating that Lakewood-Amedex Biotherapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lakewood-Amedex Biotherapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Atrinsic 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer PTIX or PMCB?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Atrinsic 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Nuvilex 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better earnings and valuation, PTIX or PMCB?

Nuvilex is trading at a lower price-to-earnings ratio than Atrinsic, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Atrinsic N/A N/A -$5.53M $2.23 0.48 Nuvilex N/A N/A -$19.42M -$3.00 N/A

Is PTIX or PMCB more profitable?

Nuvilex's return on equity of 0.25% beat Atrinsic's return on equity. Company Net Margins Return on Equity Return on Assets Atrinsic N/A N/A -379.72% Nuvilex N/A 0.25% 0.18%

Do analysts prefer CDIO or PTIX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cardio Diagnostics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Atrinsic 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Atrinsic (PTIX) Competitors

$1.06 +0.06 (+6.00%)

As of 09/4/2026 12:22 PM Eastern

Compare

PTIX vs. AQB, OSRH, LABT, PMCB, and CDIO

Should you buy Atrinsic stock or one of its competitors? Atrinsic's main competitors and comparable companies include AquaBounty Technologies (AQB), OSR (OSRH), Lakewood-Amedex Biotherapeutics (LABT), Nuvilex (PMCB), and Cardio Diagnostics (CDIO). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Atrinsic compare to AquaBounty Technologies?

Atrinsic (NASDAQ:PTIX) and AquaBounty Technologies (NASDAQ:AQB) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, profitability, valuation, analyst recommendations, media sentiment and dividends.

8.0% of Atrinsic shares are owned by institutional investors. Comparatively, 8.9% of AquaBounty Technologies shares are owned by institutional investors. 8.0% of Atrinsic shares are owned by company insiders. Comparatively, 1.0% of AquaBounty Technologies shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Atrinsic's return on equity of 0.00% beat AquaBounty Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Atrinsic	N/A	N/A	-379.72%
AquaBounty Technologies	N/A	-147.07%	-28.73%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atrinsic	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
AquaBounty Technologies	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Atrinsic had 1 more articles in the media than AquaBounty Technologies. MarketBeat recorded 1 mentions for Atrinsic and 0 mentions for AquaBounty Technologies. Atrinsic's average media sentiment score of 0.00 equaled AquaBounty Technologies'average media sentiment score.

Company	Overall Sentiment
Atrinsic	Neutral
AquaBounty Technologies	Neutral

Atrinsic has a beta of 1.77, meaning that its share price is 77% more volatile than the broader market. Comparatively, AquaBounty Technologies has a beta of 1.45, meaning that its share price is 45% more volatile than the broader market.

AquaBounty Technologies is trading at a lower price-to-earnings ratio than Atrinsic, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atrinsic	N/A	N/A	-$5.53M	$2.23	0.48
AquaBounty Technologies	N/A	N/A	-$18.49M	-$0.82	N/A

Summary

Atrinsic beats AquaBounty Technologies on 7 of the 9 factors compared between the two stocks.

How does Atrinsic compare to OSR?

Atrinsic (NASDAQ:PTIX) and OSR (NASDAQ:OSRH) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, risk, institutional ownership, profitability, earnings, media sentiment, dividends and valuation.

Atrinsic has higher earnings, but lower revenue than OSR. OSR is trading at a lower price-to-earnings ratio than Atrinsic, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atrinsic	N/A	N/A	-$5.53M	$2.23	0.48
OSR	$1.81M	4.37	-$27.06M	-$0.37	N/A

In the previous week, Atrinsic had 1 more articles in the media than OSR. MarketBeat recorded 1 mentions for Atrinsic and 0 mentions for OSR. Atrinsic's average media sentiment score of 0.00 equaled OSR'saverage media sentiment score.

Company	Overall Sentiment
Atrinsic	Neutral
OSR	Neutral

Atrinsic has a net margin of 0.00% compared to OSR's net margin of -593.15%. Atrinsic's return on equity of 0.00% beat OSR's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Atrinsic	N/A	N/A	-379.72%
OSR	-593.15%	-8.36%	-6.24%

8.0% of Atrinsic shares are owned by institutional investors. Comparatively, 55.3% of OSR shares are owned by institutional investors. 8.0% of Atrinsic shares are owned by insiders. Comparatively, 36.9% of OSR shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Atrinsic has a beta of 1.77, suggesting that its stock price is 77% more volatile than the broader market. Comparatively, OSR has a beta of 0.5, suggesting that its stock price is 50% less volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atrinsic	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
OSR	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Atrinsic beats OSR on 7 of the 11 factors compared between the two stocks.

How does Atrinsic compare to Lakewood-Amedex Biotherapeutics?

Lakewood-Amedex Biotherapeutics (NASDAQ:LABT) and Atrinsic (NASDAQ:PTIX) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, dividends, risk, earnings, analyst recommendations, valuation, media sentiment and institutional ownership.

Lakewood-Amedex Biotherapeutics is trading at a lower price-to-earnings ratio than Atrinsic, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lakewood-Amedex Biotherapeutics	N/A	N/A	-$3.85M	-$4.75	N/A
Atrinsic	N/A	N/A	-$5.53M	$2.23	0.48

Company	Net Margins	Return on Equity	Return on Assets
Lakewood-Amedex Biotherapeutics	N/A	N/A	N/A
Atrinsic	N/A	N/A	-379.72%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lakewood-Amedex Biotherapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Atrinsic	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Lakewood-Amedex Biotherapeutics had 3 more articles in the media than Atrinsic. MarketBeat recorded 4 mentions for Lakewood-Amedex Biotherapeutics and 1 mentions for Atrinsic. Lakewood-Amedex Biotherapeutics' average media sentiment score of 0.78 beat Atrinsic's score of 0.00 indicating that Lakewood-Amedex Biotherapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lakewood-Amedex Biotherapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Atrinsic	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

8.0% of Atrinsic shares are held by institutional investors. 5.4% of Lakewood-Amedex Biotherapeutics shares are held by insiders. Comparatively, 8.0% of Atrinsic shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Lakewood-Amedex Biotherapeutics and Atrinsic tied by winning 4 of the 8 factors compared between the two stocks.

How does Atrinsic compare to Nuvilex?

Atrinsic (NASDAQ:PTIX) and Nuvilex (NASDAQ:PMCB) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, media sentiment, risk, earnings, institutional ownership, analyst recommendations, valuation and profitability.

8.0% of Atrinsic shares are held by institutional investors. Comparatively, 34.2% of Nuvilex shares are held by institutional investors. 8.0% of Atrinsic shares are held by insiders. Comparatively, 11.0% of Nuvilex shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Atrinsic has a beta of 1.77, suggesting that its share price is 77% more volatile than the broader market. Comparatively, Nuvilex has a beta of 0.66, suggesting that its share price is 34% less volatile than the broader market.

Nuvilex's return on equity of 0.25% beat Atrinsic's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Atrinsic	N/A	N/A	-379.72%
Nuvilex	N/A	0.25%	0.18%

In the previous week, Atrinsic had 1 more articles in the media than Nuvilex. MarketBeat recorded 1 mentions for Atrinsic and 0 mentions for Nuvilex. Atrinsic's average media sentiment score of 0.00 equaled Nuvilex'saverage media sentiment score.

Company	Overall Sentiment
Atrinsic	Neutral
Nuvilex	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atrinsic	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Nuvilex	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Nuvilex is trading at a lower price-to-earnings ratio than Atrinsic, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atrinsic	N/A	N/A	-$5.53M	$2.23	0.48
Nuvilex	N/A	N/A	-$19.42M	-$3.00	N/A

Summary

Atrinsic beats Nuvilex on 5 of the 9 factors compared between the two stocks.

How does Atrinsic compare to Cardio Diagnostics?

Cardio Diagnostics (NASDAQ:CDIO) and Atrinsic (NASDAQ:PTIX) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, institutional ownership, profitability, dividends, valuation, analyst recommendations, earnings and media sentiment.

Atrinsic has a net margin of 0.00% compared to Cardio Diagnostics' net margin of -43,133.33%. Atrinsic's return on equity of 0.00% beat Cardio Diagnostics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cardio Diagnostics	-43,133.33%	-82.28%	-76.03%
Atrinsic	N/A	N/A	-379.72%

Cardio Diagnostics has a beta of 2.28, meaning that its share price is 128% more volatile than the broader market. Comparatively, Atrinsic has a beta of 1.77, meaning that its share price is 77% more volatile than the broader market.

8.1% of Cardio Diagnostics shares are owned by institutional investors. Comparatively, 8.0% of Atrinsic shares are owned by institutional investors. 9.0% of Cardio Diagnostics shares are owned by insiders. Comparatively, 8.0% of Atrinsic shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cardio Diagnostics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Atrinsic	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Atrinsic has lower revenue, but higher earnings than Cardio Diagnostics. Cardio Diagnostics is trading at a lower price-to-earnings ratio than Atrinsic, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cardio Diagnostics	$10K	550.56	-$6.50M	-$2.92	N/A
Atrinsic	N/A	N/A	-$5.53M	$2.23	0.48

In the previous week, Atrinsic had 1 more articles in the media than Cardio Diagnostics. MarketBeat recorded 1 mentions for Atrinsic and 0 mentions for Cardio Diagnostics. Cardio Diagnostics' average media sentiment score of 1.89 beat Atrinsic's score of 0.00 indicating that Cardio Diagnostics is being referred to more favorably in the media.

Company	Overall Sentiment
Cardio Diagnostics	Very Positive
Atrinsic	Neutral

Summary

Cardio Diagnostics and Atrinsic tied by winning 6 of the 12 factors compared between the two stocks.

Get Atrinsic News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PTIX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PTIX vs. The Competition

Export

Metric	Atrinsic	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.92M	$4.03B	$7.28B	$12.92B
Dividend Yield	N/A	3.60%	2.54%	8.90%
P/E Ratio	-0.13	12.65	272.43	25.42
Price / Sales	N/A	1,327.03	616.81	89.65
Price / Cash	N/A	107.40	77.39	52.28
Price / Book	0.54	16.15	12.85	6.17
Net Income	-$5.53M	-$22.76M	$3.47B	$349.50M
7 Day Performance	8.15%	0.30%	0.97%	-0.15%
1 Month Performance	309.58%	8.24%	5.46%	1.02%
1 Year Performance	-66.35%	49.08%	24.28%	14.50%

Atrinsic Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PTIX Atrinsic	0.0326 of 5 stars	$1.06 +6.0%	N/A	-65.8%	$1.92M	N/A	N/A	2	Gap Down
AQB AquaBounty Technologies	0.1479 of 5 stars	$1.31 +1.6%	N/A	-10.2%	$6.64M	$2.47M	N/A	100	Gap Up
OSRH OSR	0.3305 of 5 stars	$0.17 +1.5%	N/A	-62.0%	$5.88M	$1.81M	N/A	N/A	Gap Down
LABT Lakewood-Amedex Biotherapeutics	0.7571 of 5 stars	$2.49 +1.6%	N/A	N/A	$5.81M	N/A	N/A	5	News Coverage Positive News Analyst Revision Gap Down
PMCB Nuvilex	0.8468 of 5 stars	$0.54 -0.1%	N/A	-47.9%	$5.80M	N/A	N/A	4	Positive News Analyst Downgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PTIX) was last updated on 9/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Atrinsic (PTIX) Competitors

PTIX vs. AQB, OSRH, LABT, PMCB, and CDIO

How does Atrinsic compare to AquaBounty Technologies?

Summary

How does Atrinsic compare to OSR?

Summary

How does Atrinsic compare to Lakewood-Amedex Biotherapeutics?

Summary

How does Atrinsic compare to Nuvilex?

Summary

How does Atrinsic compare to Cardio Diagnostics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PTIX vs. The Competition

Atrinsic Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Atrinsic (PTIX) Competitors

PTIX vs. AQB, OSRH, LABT, PMCB, and CDIO

How does Atrinsic compare to AquaBounty Technologies?

Do institutionals and insiders have more ownership in PTIX or AQB?

Is PTIX or AQB more profitable?

Do analysts rate PTIX or AQB?

Does the media refer more to PTIX or AQB?

Which has more risk and volatility, PTIX or AQB?

Which has higher valuation & earnings, PTIX or AQB?

Summary

How does Atrinsic compare to OSR?

Which has higher valuation & earnings, PTIX or OSRH?

Does the media favor PTIX or OSRH?

Is PTIX or OSRH more profitable?

Do institutionals and insiders have more ownership in PTIX or OSRH?

Which has more risk & volatility, PTIX or OSRH?

Do analysts prefer PTIX or OSRH?

Summary

How does Atrinsic compare to Lakewood-Amedex Biotherapeutics?

Which has better valuation & earnings, LABT or PTIX?

Is LABT or PTIX more profitable?

Do analysts recommend LABT or PTIX?

Does the media favor LABT or PTIX?

Do insiders & institutionals hold more shares of LABT or PTIX?

Summary

How does Atrinsic compare to Nuvilex?

Do insiders and institutionals hold more shares of PTIX or PMCB?

Which has more risk and volatility, PTIX or PMCB?

Is PTIX or PMCB more profitable?

Does the media prefer PTIX or PMCB?

Do analysts prefer PTIX or PMCB?

Which has better earnings and valuation, PTIX or PMCB?

Summary

How does Atrinsic compare to Cardio Diagnostics?

Is CDIO or PTIX more profitable?

Which has more risk and volatility, CDIO or PTIX?

Do institutionals and insiders believe in CDIO or PTIX?

Do analysts prefer CDIO or PTIX?

Which has preferable earnings & valuation, CDIO or PTIX?

Does the media prefer CDIO or PTIX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PTIX vs. The Competition

Atrinsic Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools